3 unchanged sentences
Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
−Removed: During the three-month period ending June 30, 2024, we did not adopt or terminate any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
−Removed: The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending June 30, 2024:
−Removed: Date of Adoption
−Removed: Duration of Rule 10b5-1 Plan
−Removed: Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan
−Removed: Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan
−Removed: Chief Innovation Officer
−Removed: June 5, 2024 September 4, 2024 - December 31, 2026 — 278,612
−Removed: Wilhelmus Groenhuysen (1)
−Removed: Chief Operating Officer
−Removed: June 5, 2024 September 4, 2024 - May 31, 2025 — 1,249,563
−Removed: Gabriel Kinyip Leung
−Removed: June 5, 2024 September 4, 2024 - August 31, 2025
−Removed: (1) Includes shares held by the Groenhuysen Family Trust, in which Mr.
−Removed: Groenhuysen maintains a pecuniary interest.
−Removed: Groenhuysen does not disclaim beneficial ownership of such shares.
−Removed: During the three-month period ending June 30, 2024, none of our executive officers or directors terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
+Added: During the three-month period ending September 30, 2024 neither we nor any of our executive officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
EXHIBIT INDEX
1 unchanged sentence
Exhibit Description Form Date Number
−Removed: 10.1 NovoCure Limited 2024 Omnibus Incentive Plan #
−Removed: 8-K 6/10/2024 10.1
+Added: 10.1 Employment Agreement between Wilhelmus Groenhuysen and Novocure USA LLC effective as of October 1, 2024#
31.1 Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended
14 unchanged sentences
NovoCure Limited
−Removed: July 25, 2024 /s/ Ashley Cordova
+Added: October 30, 2024 /s/ Ashley Cordova
Ashley Cordova
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.